We are live on ! Find out more
ARTV

Artiva Biotherapeutics
ARTV

34 hedge funds and large institutions have $72.7M invested in Artiva Biotherapeutics in 2025 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 15 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

40% more capital invested

Capital invested by funds: $52.1M → $72.7M (+$20.6M)

5.24% less ownership

Funds ownership: 74.32% → 69.08% (-5.2%)

15% less funds holding

Funds holding: 40 → 34 (-6)

50% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 12

73% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 15

Holders
34
Holders Change
-6
Holders Change %
-15%
% of All Funds
0.41%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.02%
New
6
Increased
4
Reduced
15
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
+$470K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$328K
3
Marshall Wace
Marshall Wace
United Kingdom
+$300K
4
Jane Street
Jane Street
New York
+$154K
5
Renaissance Technologies
Renaissance Technologies
New York
+$140K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$2.29M
2
VP
venBio Partners
California
-$1.89M
3
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$446K
4
BlackRock
BlackRock
New York
-$309K
5
Citigroup
Citigroup
New York
-$303K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$42.3M – – –
5VM
2
5AM Venture Management
California
$10.1M – – –
VA
3
VR Adviser
New York
$6.91M – – –
VP
4
venBio Partners
California
$2.78M -$1.89M -500,468 -44%
Franklin Resources
5
Franklin Resources
California
$2.23M – – –
RCM
6
Revelation Capital Management
California
$1.28M +$1.13M +299,311 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$1.06M +$328K +86,888 +55%
Millennium Management
8
Millennium Management
New York
$931K -$170K -45,063 -17%
BlackRock
9
BlackRock
New York
$912K -$309K -81,884 -28%
Wellington Management Group
10
Wellington Management Group
Massachusetts
$833K – – –
Two Sigma Investments
11
Two Sigma Investments
New York
$621K +$470K +124,500 +611%
Renaissance Technologies
12
Renaissance Technologies
New York
$498K +$140K +37,053 +47%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$434K -$36.9K -9,779 -9%
Alyeska Investment Group
14
Alyeska Investment Group
Illinois
$429K – – –
Marshall Wace
15
Marshall Wace
United Kingdom
$341K +$300K +79,559 New
Jane Street
16
Jane Street
New York
$174K +$154K +40,671 New
UBS Group
17
UBS Group
Switzerland
$158K +$59.4K +15,730 +74%
State Street
18
State Street
Massachusetts
$154K -$90.6K -24,000 -40%
BCM
19
Bridgeway Capital Management
Texas
$150K – – –
SRL
20
Scientech Research LLC
New Jersey
$119K +$105K +27,757 New
Morgan Stanley
21
Morgan Stanley
New York
$116K -$59.5K -15,757 -37%
OAC
22
OMERS Administration Corp
Ontario, Canada
$90.5K +$79.7K +21,100 New
Goldman Sachs
23
Goldman Sachs
New York
$51.7K -$142K -37,717 -76%
PCM
24
Prelude Capital Management
New York
$45.9K -$13.6K -3,611 -25%
Russell Investments Group
25
Russell Investments Group
United Kingdom
$23.6K – – –
1
2

ARTV Hedge Fund Activity: Q4 2025 in Review

34 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Artiva Biotherapeutics (ARTV) for Q4 2025, worth a combined $72.7M — up 40% from $52.1M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of ARTV and 6 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 4 added.

The largest buyer was Two Sigma Investments, adding an estimated $470K. The largest seller was Citadel Advisors, exiting entirely with an estimated $2.29M sold.

  • 34 institutional investors held Artiva Biotherapeutics (ARTV) as of Q4 2025, down from 40 in Q3 2025.
  • Funds reported $72.7M of Artiva Biotherapeutics stock for Q4 2025, up 40% quarter-over-quarter.
  • 6 funds opened new Artiva Biotherapeutics positions in Q4 2025 and 12 closed out, a net change of -6 holders.
  • The largest Artiva Biotherapeutics buyer in Q4 2025 was Two Sigma Investments, an estimated $470K added.
  • The largest Artiva Biotherapeutics seller in Q4 2025 was Citadel Advisors, an estimated $2.29M sold.

Based on aggregated 13F filings for Q4 2025.